ABSTRACT: Background:Although the prognostic value of lncRNA small nucleolar RNA host gene 15 (SNHG15) expression in cancers has been evaluated in many studies, the results remain controversial. This meta-analysis aimed to clarify the role of SNHG15 in the prognosis of different cancer patients. Materials and Methods:Eligible studies were selected from PubMed, PMC, EMBASE, Web of Science, and Cochrane Library according to the inclusion and exclusion criteria (up to December 20, 2019). The primary outcome was overall survival (OS) and recurrence-free survival (RFS). The secondary outcome was other clinicopathological parameters (including advanced TNM stage, lymph node metastasis, distant metastases, and gender). The Cancer Genome Atlas (TCGA) dataset was used to verify the analysis results. Results:Eleven eligible studies were eventually included, involving 9 different types of cancer and 1,079 patients. The high expression of SNHG15 was indicative of a significantly poor OS of cancer patients (HR?=?1.96, 95% CI?=?1.55-2.47, P < 0.00001). Subgroup analysis showed that the high expression of SNHG15 was associated with a significantly poor OS of patients with digestive cancer (HR?=?1.91, 95% CI?=?1.38-2.66, P=0.0001), but not lung cancer (HR?=?1.83, 95% CI?=?0.89-3.76, P=0.010). The RFS of patients with high expression of SNHG15 was shorter than that of patients with low expression of SNHG15 (HR?=?2.03, 95% CI?=?1.46-2.83, P < 0.00001). In addition, high SNHG15 expression level was significantly correlated with later TNM stage (OR?=?3.05, 95% CI?=?2.31-4.02, P < 0.00001), lymphatic metastasis (OR?=?3.20, 95% CI?=?2.30-4.45, P < 0.00001), and distant metastasis (OR?=?5.05, 95% CI?=?2.15-11.85, P=0.0002). The TCGA verification results were consistent with those observed in our meta-analysis. Conclusion:High expression of the long noncoding RNA SNHG15 in cancer tissue samples predicts an unfavorable prognosis for cancer patients. LncRNA SNHG15 can be used as an adverse prognostic biomarker for cancer patients.
